@article{3e6eedce001a4eb380ddb7ec382dabef,
title = "No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial",
keywords = "SARS-CoV-2, COVID-19, Spironolactone, RECEPTOR, ACE2, RISK",
author = "J.P. Ferreira and N. Girerd and \{Brunner-La Rocca\}, H.P. and P. Pellicori and J.G. Cleland and P. Rossignol and F. Zannad",
note = "Funding Information: HOMAGE was funded by a grant from the European Union 7th Framework Programme for Research and Technological Development (HEALTH-F7-305507) HOMAGE (EU FP7 305507 http://www.homage-hf.eu ). JPF, PR, NG and FZ are supported by the RHU Fight-HF , a public grant overseen by the French National Research Agency (ANR) as part of the second “Investissements d{\textquoteright}Avenir” programme (reference: ANR-15-RHUS-0004), by the French PIA project “ Lorraine Universit{\'e} d{\textquoteright}Excellence ” (reference: ANR-15-IDEX-04-LUE), Contrat de Plan {\'E}tat Lorraine IT2MP and FEDER Lorraine . Funding Information: HOMAGE was funded by a grant from the European Union 7th Framework Programme for Research and Technological Development (HEALTH-F7-305507) HOMAGE (EU FP7 305507 http://www.homage-hf.eu). JPF, PR, NG and FZ are supported by the RHU Fight-HF, a public grant overseen by the French National Research Agency (ANR) as part of the second ?Investissements d'Avenir? programme (reference: ANR-15-RHUS-0004), by the French PIA project ?Lorraine Universit? d'Excellence? (reference: ANR-15-IDEX-04-LUE), Contrat de Plan ?tat Lorraine IT2MP and FEDER Lorraine.",
year = "2021",
month = dec,
day = "1",
doi = "10.1016/j.acvd.2021.10.003",
language = "English",
volume = "114",
pages = "814--817",
journal = "Archives of Cardiovascular Diseases",
issn = "1875-2136",
publisher = "Elsevier Masson s.r.l.",
number = "12",
}